For example, simulations using an ePD model formed from 34 nonlinear ordinary differential equations predicted the effect of EGFR inhibition (e.g., by gefitinib) on tumour growth after adjusting for the effects of DNA methylation status to the RASAL1 promoter, a coding SNP in RKIP/PEBP and altered miR-221 expression, which all differentially perturb downstream EGFR signalling.88 Drug-induced inhibition of 80% of EGFR activity was assumed. The gene discussed is PEBP1; the disease is neoplasm.